Figure 2.
Percentage of immunocompromised and immunocompetent young patients shedding hPIV-3. The duration of viral shedding was significantly higher in immunocompromised patients.
Percentage of immunocompromised and immunocompetent young patients shedding hPIV-3. The duration of viral shedding was significantly higher in immunocompromised patients.